OKUR NASDAQ
OnKure Therapeutics, Inc.
1W: -11.7%
1M: -27.7%
3M: -44.4%
YTD: -13.5%
1Y: -4.1%
3Y: -96.6%
5Y: -97.0%
$2.56
+0.02 (+0.79%)
Weekly Expected Move ±7.5%
$2
$2
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2024-05-13
Earliest Filing
2026-03-30
Latest Filing
partner: 5
investor: 1
target: 1
Counterparties (Filed by OKUR)
7 relationshipsCompanies named in OKUR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| AI Biotechnology LLC | — | investor | Lead Investor in the private placement securities purchase agreement. | 2026-03-30 | View |
| Leerink Partners LLC | — | partner | Lead placement agent for the private placement. | 2026-03-30 | View |
| Evercore Group L.L.C. | EVR | partner | Co-placement agent for the private placement. | 2026-03-30 | View |
| LifeSci Capital LLC | — | partner | Co-placement agent for the private placement. | 2026-03-30 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Co-placement agent for the private placement. | 2026-03-30 | View |
| Leerink Partners LLC | — | partner | Sales agent for the at-the-market offering of Class A common stock | 2025-11-06 | View |
| OnKure, Inc. | OKUR | target | Target company in a merger agreement with Reneo Pharmaceuticals, Inc. | 2024-05-13 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Officer/Director Change; Exhibits | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-06-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-03-30 | Material Agreement; Unregistered Equity Sales; Officer/Director Change; Other Events; Exhibits | Agreement | View |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-06 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-28 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-07 | Changes in Registrant's Certifying Accountant; Other Events; Financial Statements and Exhibits | View | |
| 2024-10-08 | Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Materia | Acquisition | View |
| 2024-10-02 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-09-20 | Other Events | View | |
| 2024-09-13 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-05-13 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Changes in Contro | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR